Evidence map›Paper›PMID 33269702›Full record

ArticleNeuroImage. Clinical2020

Age-dependent cut-offs for pathological deep gray matter and thalamic volume loss using Jacobian integration.

Roland Opfer, Julia Krüger, Lothar Spies, Marco Hamann, Carla A Wicki, Hagen H Kitzler, Carola Gocke, Diego Silva, Sven Schippling

Open access · goldAbstract read
In one paragraph

Article in NeuroImage. Clinical, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. BrainLossNet: a fast, accurate and robust method to estimate brain volume loss from longitudinal MRI.International journal of computer assisted radiology and surgery · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

Roland Opferjung diagnostics GmbH, Hamburg, Germany. Electronic address: roland.opfer@jung-diagnostics.de.
Julia Krügerjung diagnostics GmbH, Hamburg, Germany.
Lothar Spiesjung diagnostics GmbH, Hamburg, Germany.
Marco Hamannjung diagnostics GmbH, Hamburg, Germany.
Carla A WickiMultimodal Imaging in Neuroimmunological Diseases (MINDS), University of Zurich, Zurich, Switzerland; Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
Hagen H KitzlerInstitute of Diagnostic and Interventional Neuroradiology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany.
Carola GockeConradia Medical Prevention Hamburg, Hamburg, Germany.
Diego SilvaBristol Myers Squibb, Princeton, NJ, United States.
Sven SchipplingMultimodal Imaging in Neuroimmunological Diseases (MINDS), University of Zurich, Zurich, Switzerland; Center for Neuroscience Zurich (ZNZ), ETH Zurich, Zurich, Switzerland.
Jungheinrich (Germany) · DEBristol-Myers Squibb (United States) · USETH Zurich · CHMSH Medical School Hamburg – University of Applied Sciences and Medical University · DEUniversity Hospital Carl Gustav Carus · DEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSeveral recent studies indicate that deep gray matter or thalamic volume loss (VL) might be promising surrogate markers of disease activity in multiple sclerosis (MS) patients. To allow applying these markers to individual MS patients in clinical routine, age-dependent cut-offs distinguishing physiological from pathological VL and an estimation of the measurement error, which provides the confidence of the result, are to be defined.

methodsLongitudinal MRI scans of the following cohorts were analyzed in this study: 189 healthy controls (HC) (mean age 54 years, 22% female), 98 MS patients from Zurich university hospital (mean age 34 years, 62% female), 33 MS patients from Dresden university hospital (mean age 38 years, 60% female), and publicly available reliability data sets consisting of 162 short-term MRI scan-rescan pairs with scan intervals of days or few weeks. Percentage annualized whole brain volume loss (BVL), gray matter (GM) volume loss (GMVL), deep gray matter volume loss (deep GMVL), and thalamic volume loss (ThalaVL) were computed deploying the Jacobian integration (JI) method. BVL was additionally computed using Siena, an established method used in many Phase III drug trials. A linear mixed effect model was used to estimate the measurement error as the standard deviation (SD) of model residuals of all 162 scan-rescan pairs For estimation of age-dependent cut-offs, a quadratic regression function between age and the corresponding annualized VL values of the HC was computed. The 5th percentile was defined as the threshold for pathological VL per year since 95% of HC subjects exhibit a less pronounced VL for a given age. For the MS patients BVL, GMVL, deep GMVL, and ThalaVL were mutually compared and a paired t-test was used to test whether there are systematic differences in VL between these brain regions.

resultsSiena and JI showed a high agreement for BVL measures, with a median absolute difference of 0.1% and a correlation coefficient of r = 0.78. Siena and GMVL showed a similar standard deviation (SD) of the scan-rescan error of 0.28% and 0.29%, respectively. For deep GMVL, ThalaVL the SD of the scan-rescan error was slightly higher (0.43% and 0.5%, respectively). Among the HC the thalamus showed the highest mean VL (-0.16%, -0.39%, and -0.59% at ages 35, 55, and 75, respectively). Corresponding cut-offs for a pathological VL/year were -0.68%, -0.91%, and -1.11%. The MS cohorts did not differ in BVL and GMVL. However, both MS cohorts showed a significantly (p = 0.05) stronger deep GMVL than BVL per year.

conclusionIt might be methodologically feasible to assess deep GMVL using JI in individual MS patients. However, age and the measurement error need to be taken into account. Furthermore, deep GMVL may be used as a complementary marker to BVL since MS patients exhibit a significantly stronger deep GMVL than BVL.

Indexed as

Gray MatterMultiple SclerosisAdultAgedAtrophyBrainFemaleHumansMagnetic Resonance ImagingMaleMiddle AgedReproducibility of ResultsAging, multiple sclerosisBrain atrophyDeep gray matter volume lossGray matter volume lossJacobian integrationSienaThalamic volume loss

Identifiers

PMID33269702
PMCPMC7645288
OpenAlexW3094985679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.